ANEW MEDICAL, INC. Announces Patents Issued in Major Asian Markets for use of Genetic Therapy in the Treatment of Alzheimer’s Disease and ALS

Rhea-AI Summary

ANEW MEDICAL, INC. (NASDAQ: WENA) has announced the issuance of patents in major Asian markets for its genetic therapy approach to treating Alzheimer's disease and ALS. The company has secured patent number HK1259628 in Hong Kong and patent number CN 117126829A in mainland China, protecting its novel secreted Klotho protein and gene delivery system.

These patents cover the development of genetic approaches for treating neurodegenerative diseases, including Alzheimer's, Parkinson's, and ALS. The intellectual property was exclusively licensed worldwide from UNIVERSITAT AUTÒNOMA DE BARCELONA and INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS.

ANEW plans to begin human testing of its innovative treatment in late 2025. The company's CEO, Dr. Joseph Sinkule, emphasized the importance of these patents in identifying clinical trial sites and corporate partners in the Chinese market.

Positive

• Secured patents in Hong Kong and mainland China for novel genetic therapy approach
• Patents cover treatment of major neurodegenerative diseases including Alzheimer's, Parkinson's, and ALS
• Exclusive worldwide license for the intellectual property
• Plans to begin human testing in late 2025
• Potential for partnerships and clinical trials in the large Chinese market

Negative

• Human testing not scheduled to begin until late 2025, indicating a long timeline for potential product development
• Competitive market with high prevalence of Alzheimer's disease in target regions

Insights

Biotech Patent Analyst

The issuance of patents in China, Hong Kong and Shanghai for ANEW MEDICAL's Klotho-based therapies is a significant milestone. These patents protect the company's novel secreted Klotho protein and gene delivery system for treating neurodegenerative diseases like Alzheimer's, Parkinson's and ALS.

This intellectual property protection in major Asian markets is crucial for ANEW's future. It paves the way for clinical trials and potential partnerships in the world's largest Alzheimer's patient population. The $ value of this market is substantial, given China's 10% prevalence rate in the 60+ age group.

However, investors should note that human testing is planned for late 2025, indicating a long runway to potential commercialization. The company's ability to secure funding and partnerships for clinical development will be critical in the coming years.

Neurodegenerative Disease Specialist

ANEW MEDICAL's approach using the Klotho protein is innovative and promising. Klotho has been shown to have neuroprotective effects and could potentially slow or halt the progression of neurodegenerative diseases.

The company's dual approach of delivering Klotho as a protein or via gene therapy offers flexibility in treatment strategies. This could be particularly beneficial in addressing the complex nature of diseases like Alzheimer's.

However, it's important to note that while preclinical results are exciting, the path to FDA approval is long and challenging. Many promising Alzheimer's treatments have failed in late-stage trials. Investors should monitor the progress of ANEW's planned human trials in 2025 for early indicators of efficacy and safety.

Global Healthcare Market Analyst

The patent issuance in major Asian markets positions ANEW MEDICAL strategically in the rapidly growing global neurodegenerative disease market. With China having the world's largest Alzheimer's patient population and Japan being a "super-aging" country, the potential market size is substantial.

However, investors should consider the competitive landscape. Several big pharma companies and biotech firms are also developing Alzheimer's treatments. ANEW's success will depend on the efficacy of its Klotho-based approach compared to other emerging therapies.

The company's focus on both U.S./European and Asian markets is prudent, given the high prevalence of Alzheimer's in these regions. This global strategy could provide multiple commercialization opportunities if clinical trials prove successful. Keep an eye on ANEW's ability to secure partnerships or funding for its ambitious clinical development plans.

• Patents issued in mainland China protect the Company’s novel secreted Klotho protein and Its gene delivery system
• Recent Patents issued in Hong Kong and Shanghai support protection to develop treatments for Alzheimer’s Disease and other neurodegenerative diseases

NEW YORK, Aug. 08, 2024 (GLOBE NEWSWIRE) -- ANEW MEDICAL, INC. (“ANEW” or “the Company”) (NASDAQ: WENA) a US-based biotechnology company focused on developing cell- and gene-based treatments to affect aging and age-related diseases, announces the grant and issuance of patent number HK1259628 protecting the development of novel genetic approaches for the treatment of neurodegenerative diseases to include Alzheimer’s disease, Parkinson’s diseases and amyotrophic lateral sclerosis (“ALS”).

The Company previously announced that it had been granted this key patent in China (Patent No. CN 117126829A) for the use of ANEW’s Klotho protein and Klotho gene delivery and expression systems in the treatment of cognition, memory and neurodegenerative diseases. This intellectual property was licensed by ANEW from UNIVERSITAT AUTÒNOMA DE BARCELONA (UAB) and INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS (ICREA) in Barcelona, Spain on an exclusive worldwide basis.

Dr. Joseph Sinkule, the Founder and CEO of ANEW, stated: “With intellectual property protection in Hong Kong, Beijing, Shanghai, and throughout the Chinese market for our innovative way of treating neurodegenerative diseases like Alzheimer’s diseases (“AD”), identifying clinical trial sites and corporate partners to evaluate the efficacy and safety of our product candidates is very important to ANEW.”

Dr. Sinkule continued: “The patents, comprising the secreted form of the human Klotho protein (“s-KL”) being delivered as a protein or by delivery of a sequence of the human gene that makes the protein in the body, are projected to be a major advance in how we treat or prevent the progression of these neurologic diseases. We are particularly excited about the preclinical results and plan to begin human testing in late 2025.”

The aging population in China is affected by the same age-related diseases we are fighting in the US and Europe. According to a recent report, China has the highest number of Alzheimer's patients in the world, with nearly 10 million people aged 60 and older suffering from the disease. Additionally, Asia in general is experiencing the fastest growth in the elderly population is taking place. Japan is considered a “super-aging” country, and the number of people with AD in Japan is expected to reach approximately 6.5–7 million by 2025, very similar to the prevalence of AD in the U.S. (approximately 7 million cases). AD and AD-associated dementia are very common in Western Europe and Finland, with North America following close behind. While AD is least common in Sub-Saharan Africa, African-Americans in the U.S. are about twice as likely to have Alzheimer's disease or other forms of dementia as Caucasian and Hispanic Americans.

About ANEW MEDICAL, INC.:
ANEW MEDICAL, INC. (NASDAQ: WENA) is a biopharmaceutical company specializes in the development of patented, novel disease-modifying technologies targeting the brain and central nervous system (CNS) that are seen as key developments in treating neurodegenerative and age-related disorders. The Company obtained exclusive worldwide rights to platform technologies and knowhow to develop cutting edge protein, gene and cell therapies to treat age-related pathologies such as Alzheimer’s and Parkinson’s Disease, ALS, multiple sclerosis and rare neurodegenerative diseases. The company is managed by a team of individuals and advisors who are highly experienced in biopharmaceutical product development and commercialization.

For more information, contact:
Eric Boyd
Investor Relations
Email: IR@anewmeds.com

Forward-Looking Statements:
This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Without limiting the generality of the foregoing, the forward-looking statements in this press release include descriptions of the Company’s future commercial operations. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, such as the Company’s inability to implement its business plans, identify and realize additional opportunities, or meet or exceed its financial projections and changes in the regulatory or competitive environment in which the Company operates. You should carefully consider the foregoing factors and the other risks and uncertainties described in the documents filed or to be filed by the Company with the U.S. Securities and Exchange Commission (the “SEC”) from time to time, which could cause actual events and results to differ materially from those contained in the forward-looking statements. Copies of these documents are available on the SEC’s website, www.sec.gov. All information provided herein is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.

FAQ

What patents has ANEW MEDICAL (WENA) recently been granted for its Alzheimer's and ALS treatments?

ANEW MEDICAL has been granted patent number HK1259628 in Hong Kong and patent number CN 117126829A in mainland China for its novel secreted Klotho protein and gene delivery system, used in treating neurodegenerative diseases like Alzheimer's and ALS.

When does ANEW MEDICAL (WENA) plan to begin human testing for its neurodegenerative disease treatments?

ANEW MEDICAL plans to begin human testing of its innovative treatment for neurodegenerative diseases in late 2025.

What is the significance of the Chinese market for ANEW MEDICAL's (WENA) Alzheimer's treatment?

China has the highest number of Alzheimer's patients globally, with nearly 10 million people aged 60 and older affected. This makes it a important market for ANEW MEDICAL's treatments, offering significant potential for clinical trials and partnerships.

How does ANEW MEDICAL's (WENA) treatment for neurodegenerative diseases work?

ANEW MEDICAL's treatment involves the secreted form of the human Klotho protein (s-KL), delivered either as a protein or through a sequence of the human gene that produces the protein in the body, aimed at treating or preventing the progression of neurodegenerative diseases.